Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more

Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at c ... Read more

Novo Nordisk to achieve target of 100% renewable power in production and launche ... Read more

Novo Nordisk receives positive opinion from the European regulatory authorities ... Read more

Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more

Novo Nordisk A/S - Share repurchase programme ... Read more

Novo Nordisk A/S - Share repurchase programme ... Read more

Novo Nordisk A/S - Share repurchase programme ... Read more

Silent period ,

Financial statement for the first six months of 2019,

Ex-dividend,

Record date,